Hugo Sigman, holder of Insud Group, which will manufacture the coronavirus vaccine in the country, spoke of the importance of the cooperation of the scientific sector and the public-private structuring for the country to achieve “produce with added value and generate exports” to “no longer depend on the dollar.”
The businessman was present this morning at the Argentina Vision 2020/40, organized by ADBlick Agro, Bioceres and the Agribusiness and Food Center of the Austral University for the benefit of Bisblick Young Talent, where the leadership and leaders of the agribusiness give their vision about Argentina in the next world.
In recent weeks, the founder of the mAbxience laboratory charged new public relevance when it was announced that it will be part of the production process of a coronavirus vaccine in Argentina, developed by the pharmaceutical company Astra Zeneca and the British University of Oxford.
Sigman explained how the process of creating the plant “for the manufacture of vaccines in Argentina” was like after the spread of influenza A. For him, “The only vaccine in the world was for developed countries” and he clarified that this motive prompted him to assemble and develop the necessary resources for the country to have scientific advances for a future disease.
“Now we are working so that Argentina does not run out of vaccines to prevent Covid-19”, said. The businessman also stressed that the country lacks working groups in basic research, that is why Insud decided to get involved in this line “and create products that are patented throughout the world.”
“We have just put the equine serum treatment for Covid into clinical studies,” he commented. “The company never has to be inspired by profit but by excellence.” In his opinion, the product must always be the best and “excellence has to be present in the entire group of people in the company”.
The businessman also referred to a small investment fund that was started together with the Argentine Chamber of Biotechnology in order to develop projects for young people who wanted to become entrepreneurs. “Investments were received from other countries, from companies linked to agriculture that sought to acquire the necessary resources to be able to develop. We are inspired by companies related to the agricultural sector, such as Bioceres “, story.
That company said, It is like a large cooperative of agricultural producers with 300 members, with those who get together “to try to create a plant biotechnology company in Argentina and with local research.”
The company, which today is listed on the United States stock market, is a company that today has a worldwide patented development, the drought tolerance gene HB4. This product, he said, was born from a cooperation with another company in the producing sector.
“This cooperative model is a bit altruistic, trying to develop a company related to plant technology in a country with such a strong relationship in agricultural activity. It inspired us in the Chamber to found the investment fund, “he explained. According to him, this type of action is impossible to achieve without cooperation from the scientific sector and the other party involved.
ALSO
– .
